These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 15503155)

  • 1. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.
    Schober A
    Cell Tissue Res; 2004 Oct; 318(1):215-24. PubMed ID: 15503155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models of Parkinson's disease.
    Betarbet R; Sherer TB; Greenamyre JT
    Bioessays; 2002 Apr; 24(4):308-18. PubMed ID: 11948617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
    Tapias V; Cannon JR; Greenamyre JT
    J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental models of Parkinson's disease: insights from many models.
    Tolwani RJ; Jakowec MW; Petzinger GM; Green S; Waggie K
    Lab Anim Sci; 1999 Aug; 49(4):363-71. PubMed ID: 10480640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
    Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
    Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Models of Parkinson's disease.
    Orth M; Tabrizi SJ
    Mov Disord; 2003 Jul; 18(7):729-37. PubMed ID: 12815651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
    Santiago RM; Barbieiro J; Lima MM; Dombrowski PA; Andreatini R; Vital MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1104-14. PubMed ID: 20547199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
    Deumens R; Blokland A; Prickaerts J
    Exp Neurol; 2002 Jun; 175(2):303-17. PubMed ID: 12061862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
    Schmidt WJ; Alam M
    J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling neurodegenerative diseases in vivo review.
    von Bohlen Und Halbach O
    Neurodegener Dis; 2005; 2(6):313-20. PubMed ID: 16909014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marmoset monkey models of Parkinson's disease: which model, when and why?
    Eslamboli A
    Brain Res Bull; 2005 Dec; 68(3):140-9. PubMed ID: 16325013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease.
    Bretaud S; Lee S; Guo S
    Neurotoxicol Teratol; 2004; 26(6):857-64. PubMed ID: 15451049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
    Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
    Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
    Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
    J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.